SG Americas Securities LLC Has $8.17 Million Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

SG Americas Securities LLC grew its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 967.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 24,593 shares of the company’s stock after purchasing an additional 22,289 shares during the quarter. SG Americas Securities LLC owned about 0.08% of Medpace worth $8,171,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Stone House Investment Management LLC acquired a new position in shares of Medpace during the third quarter worth approximately $33,000. Ashton Thomas Securities LLC bought a new stake in shares of Medpace during the 3rd quarter worth $37,000. Capital Performance Advisors LLP bought a new stake in Medpace in the third quarter worth about $46,000. True Wealth Design LLC raised its holdings in shares of Medpace by 16,800.0% in the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after purchasing an additional 168 shares during the period. Finally, Northwestern Mutual Wealth Management Co. lifted its position in shares of Medpace by 95.7% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 225 shares of the company’s stock valued at $93,000 after buying an additional 110 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on MEDP shares. William Blair reiterated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Redburn Atlantic started coverage on Medpace in a research report on Monday, October 14th. They set a “buy” rating and a $404.00 price objective on the stock. UBS Group downgraded shares of Medpace from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $420.00 to $350.00 in a research note on Friday, September 27th. StockNews.com lowered Medpace from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Finally, Baird R W cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $380.56.

Medpace Stock Performance

Shares of MEDP stock opened at $347.90 on Friday. Medpace Holdings, Inc. has a fifty-two week low of $286.76 and a fifty-two week high of $459.77. The firm has a market capitalization of $10.81 billion, a price-to-earnings ratio of 30.46, a PEG ratio of 1.78 and a beta of 1.36. The stock’s 50-day simple moving average is $339.40 and its 200-day simple moving average is $356.05.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The business had revenue of $533.32 million during the quarter, compared to analyst estimates of $540.99 million. During the same quarter last year, the business posted $2.22 EPS. The company’s revenue was up 8.3% on a year-over-year basis. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.